HIV prevention drug lenacapavir approved by FDA as twice-yearly injection
The U.S. Food and Drug Administration has recently given approval for the drug lenacapavir, developed by Gilead Sciences, as a groundbreaking new method for preventing HIV. This medication, known as Yeztugo, is administered as a twice-yearly injection and has shown remarkable efficacy in clinical trials, with 99.9% of participants who received it remaining HIV negative.
Daniel O’Day, the chairman and CEO of Gilead Sciences, hailed this approval as a major milestone in the fight against HIV. He expressed confidence that Yeztugo will revolutionize the prevention of HIV and potentially bring an end to the epidemic once and for all.
Despite this significant advancement, concerns have been raised about the Trump administration’s recent decision to cut funding for HIV vaccine research. Last month, funding for a range of HIV vaccine projects was terminated, with officials suggesting that existing strategies were sufficient to combat the virus.
Dr. Barton Ford Haynes, from the Duke Human Vaccine Institute, acknowledged the importance of lenacapavir but emphasized the ongoing need for a vaccine. He stressed that significant progress had been made in HIV vaccine development and that cutting off funding at this critical juncture could set back research efforts by a decade.
Dennis Burton, an immunology professor at Scripps Research, echoed these concerns, warning that the consequences of halting HIV vaccine research could be long-lasting. He emphasized that restarting such research in the future would not be a simple task and could result in the loss of valuable scientific expertise and progress.
As discussions around HIV funding and research continue, it is clear that both lenacapavir and the pursuit of an HIV vaccine play crucial roles in the fight against the virus. The approval of Yeztugo offers new hope for HIV prevention, while the importance of ongoing vaccine research cannot be understated.
This article was contributed to by Dr. Céline Gounder and Alexander Tin, with Sara Moniuszko serving as the health and lifestyle reporter at CBSNews.com. With a background in wellness reporting and a focus on breaking news, she brings a wealth of experience to covering important health developments like the approval of lenacapavir.
